


N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides as 5-HT₇ Receptor Agents


Marcello Leopoldo, Francesco Berardi, Nicola A. Colabufo, Enza Lacivita, Roberto Perrone, and Vincenzo Tortorella

Università degli Studi di Bari, Dipartimento Farmaco-Chimico
via Orabona, 4, 70125, Bari, Italy

The 5-HT₇ receptor (5-HT₇R) has been found by the application of molecular cloning and it has been identified in rat, mouse, human, pig, and guinea pig. Although the biological functions of the 5-HT₇Rs are poorly understood, preliminary evidence suggests that it may be involved in depression, control of circadian rhythms, and relaxation of vascular smooth muscles. For these reasons the 5-HT₇R has become a target for the development of novel drugs. During the last decade considerable research efforts have been directed towards the identification of selective 5-HT₇R ligands, allowing the identification of several antagonists, such as SB-269970 (**1**) and a limited number of agonists, as compound **2**. [1]




SB-269970 (**1**)




2

However, the reported 5-HT₇R agents display low potency, modest selectivity, and low metabolic stability. Therefore, the search for selectively-acting 5-HT₇R ligands as pharmacological tools or potential drugs is still open. In a recent paper [2], we have described the identification of a series of high affinity 5-HT₇R ligands based on the *N*-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamide structure **3**. In particular, we observed that all structural modifications introduced on either the 1,2,3,4-tetrahydronaphthalenyl nucleus or on the linker between this particular group and the *N*-(2-methoxyphenyl)piperazine moiety influenced only the 5-HT₇R affinity and not the selectivity over 5-HT_{1A} receptor. In contrast, modifications of the aryl group linked to the piperazine ring resulted in major changes in 5-HT₇R affinity. For this reason, we have further evaluated other substituents on the arylpiperazine moiety with the aim of modulating the activity on 5-HT₇ receptors of these ligands (structure **4**). The outcomes of this research will be presented.



3



4

[1] Leopoldo, M. *Curr. Med. Chem.* **2004**, *11*, 629-661.

[2] Leopoldo, M.; Berardi, F.; Colabufo, N. A.; Contino, M.; Lacivita, E.; Niso, M.; Perrone, R.; Tortorella, V. *J. Med. Chem.* **2004**, *47*, 6616-6624.